Clinical Trial Update: Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating how different doses of colistin affect clinical outcomes in pediatric cancer patients with gram-negative infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Gram-negative Bacterial Infections

Drugs mentioned

• Colistin (colistin)

Snippet

Sponsor: National Cancer Institute, Egypt | Conditions: Gram-Negative Bacterial Infections, Pediatric Cancer | Phase 4 | Status: COMPLETED